Ser647

Site Information
RLPNRIPsLRMLRSF SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 18260319
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 12 )
Disease tissue studied:	breast cancer ( 3 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 , 3 ) , lung cancer ( 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , non-small cell lung cancer ( 6 , 8 , 9 , 10 ) , non-small cell lung adenocarcinoma ( 6 , 7 , 8 , 9 , 10 ) , non-small cell large cell lung carcinoma ( 6 , 8 ) , non-small cell squamous cell lung carcinoma ( 7 ) , small-cell lung cancer ( 4 , 5 )
Relevant cell line - cell type - tissue:	breast ( 2 , 3 ) , Cal-12T (pulmonary) ( 10 ) , DMS153 (pulmonary) ( 9 ) , DMS53 (pulmonary) ( 5 ) , DMS79 (pulmonary) ( 4 ) , HCC15 (pulmonary) ( 7 ) , HCC44 (pulmonary) ( 10 ) , HCC78 (pulmonary) ( 8 ) , HeLa (cervical) ( 12 ) , LOU-NH91 (squamous) ( 7 ) , lung ( 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , NCI-H128 (pulmonary) ( 4 ) , NCI-H1299 (pulmonary) ( 6 ) , NCI-H1417 (pulmonary) ( 4 ) , NCI-H1437 (pulmonary) ( 9 , 10 ) , NCI-H1666 (pulmonary) ( 10 ) , NCI-H1703 (squamous) ( 7 ) , NCI-H1734 (pulmonary) ( 6 ) , NCI-H1781 (pulmonary) ( 8 ) , NCI-H1944 (pulmonary) ( 6 ) , NCI-H2073 (pulmonary) ( 7 , 9 ) , NCI-H209 (pulmonary) ( 4 , 9 ) , NCI-H2228 (pulmonary) ( 8 ) , NCI-H2342 (pulmonary) ( 7 ) , NCI-H2405 (pulmonary) ( 10 ) , NCI-H3122 (pulmonary) ( 8 ) , NCI-H358 (pulmonary) ( 6 ) , NCI-H446 (pulmonary) ( 5 ) , NCI-H460 (pulmonary) ( 6 ) , NCI-H524 (pulmonary) ( 4 ) , NCI-H526 (pulmonary) ( 5 ) , NCI-H661 (pulmonary) ( 8 ) , NCI-H69 (pulmonary) ( 5 ) , NCI-H82 (pulmonary) ( 5 ) , NCI-H838 (pulmonary) ( 9 ) , Vero E6-S ('epithelial, kidney') ( 1 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
7	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
8	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
9	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
10	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
11	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
12	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info